No abstract

The Authors report an accidental gas exposure of Chlorine gas in a worker. This accident is very uncommon and can lead to important life-threatening conditions, such as Reactive Airway Disfunction Syndrome (RADS) and Acute Respiratory Distress Syndrome (ARDS) with important pulmonary disfunctions and even death. This syndrome results are reversible when a quick and appropriate intensive treatment is performed.

Related Quality of Life [OABq-HRQL]), somatic symptoms, and pain syndromes. Participants were categorized into 3 groups, (1) Neither (2) Either or (3) Both, based on their report of painful urgency and/or painful filling. Multivariable regression analyses were performed to determine factors predictive of have either or both painful urgency and/or painful filling.RESULTS: Of 218 women with OAB symptoms, 46% (n¼101) had neither painful urgency nor painful filling, 43% (n¼94) had either, and 11% (n¼23) had both. There was an increase in average OAB-SS, pain intensity, and somatic symptom score, and a decrease in OAB-HRQL from neither > either > both. Controlling for age, women with either or both urologic pain symptoms had an increase in somatic symptom score by 1.5 and 3 points and an increase in pain intensity by 3 and 6.5 points, respectively, compared to women in the neither group. Additionally, women with either or both symptoms were 2.9 and 3.5 times more likely to have irritable bowel syndrome and 3.3 and 4.5 times, respectively, more likely to have chronic pelvic pain.CONCLUSIONS: In this group of women with OAB, without IC/ BPS, the majority reported either painful urgency, painful filling, or both. Experiencing painful urgency and/or filling was associated with increased somatic symptom burden and pain intensity. Additionally, women with either or both symptoms were more likely to have chronic pain conditions, hypothesized to have a common central pathophysiology. These findings support the hypothesis that OAB and IC/BPS diagnoses may represent a continuum of bladder hypersensitivity with women experiencing pain being more likely to also have underlying central sensitization mechanisms.

This study investigates whether the application of Hemopatch, a novel hemostatic patch, could prevent lymphatic leak after robotic-assisted radical prostatectomy (RARP) and bilateral pelvic lymph node dissection (BPLND). This is a prospective, single-center, phase III randomized controlled trial investigating the efficacy of Hemopatch in preventing lymphatic leak after RARP and BPLND. Participants were randomized to receive RARP and BPLND, with or without the use of Hemopatch, with an allocation ratio of 1:1. The primary outcome is the total drain output volume. The secondary outcomes include blood loss, operative time, lymph node yield, duration of drainage, drain output per day, hospital stay, transfusion and 30-day complications. A total of 32 patients were recruited in the study. The Hemopatch group had a significantly lower median total drain output than the control group (35 mL vs. 180 mL, p = 0.022) and a significantly lower drain output volume per day compared to the control group (35 mL/day vs. 89 mL/day, p = 0.038). There was no significant difference in the other secondary outcomes. In conclusion, the application of Hemopatch in RARP and BPLND could reduce the total drain output volume and the drain output volume per day. The use of Hemopatch should be considered to prevent lymphatic leakage after RARP and BPLND.